DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to inform that news of recent FDA Cancer Drug Approval puts Cannabis Science in a very good position moving forward with its current Cancer solutions. Erivedge was given a fast six-month review because there are no approved treatments for advanced basal cell carcinoma. See FDA Announcement here. “For the FDA to approve a drug w...  Full Article  @ BusinessWire - 3 months ago